- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Black Swan Graphene
Jindalee Lithium
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Reuters reported that Belgian chemical company Solvay (FWB:SOL) is planning on buying its US counterpart, Cytec Industries (NYSE:CYT) for $5.5 billion. Both Solvay and Cytec are involved in the separation of rare earth elements from concentrates.
Reuters reported that Belgian chemical company Solvay (FWB:SOL) is planning on buying its US counterpart, Cytec Industries (NYSE:CYT) for $5.5 billion. Both Solvay and Cytec are involved in the separation of rare earth elements from concentrates.
As quoted in the publication:
Cytec, which makes most of its sales in North America, has 4,600 employees worldwide and annual sales of about $2.0 billion.
It makes composite and adhesive materials for the aerospace and automotive industries and reagent chemicals used in the mining sector for mineral processing and solvent extraction.
Solvay said in a statement on Wednesday it would pay $75.25 per share for Cytec in cash, which closed at $58.39 on Tuesday.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â